News

Synta is currently enrolling patients in a Phase 2 single-arm, open-label, single-agent study of STA-9090 in patients with stage IIIB or IV non-small cell lung cancer, with patient

Patients in both arms received standard of care treatment for severe sepsis in an intensive care unit (ICU) setting. As previously reported, the trial achieved its primary endpoint

The ‘GreenVax Project’ will demonstrate evidence of concept for a large-scale facility producing vaccine using Nicotiana plants grown hydroponically in a contained environment. iBio claimed that its green

AFFiRiS said that the specific reason for the ‘outing’ of project no 4 was the approval of public research promotion funds by the FFG. The vaccine is targeting

Both agencies have consented to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the US and the

Completing their strategic alliance in November 2008 to form the hybrid business model, Daiichi Sankyo and Ranbaxy have been moving forward to fully leverage the model. In addition

The acceptance of the lorcaserin NDA filing confirms that the application is sufficiently complete to permit a substantive review, and the PDUFA date is the goal date for

Robert Melamede, president and CEO of Cannabis Science, said: “We are in the final stages before Cannabis Science files with the FDA for clinical trials. There is a

The article, entitled ‘Hereditary Breast and Ovarian Cancer Testing Integration and Outcomes within Community Oncology Practices,’ was published in the February 2010 issue of the journal Community Oncology.